Introduction
============

Human genetic defects in the growth hormone (GH) -- IGF-I axis causing disruption of the IGF system are usually associated with GH insensitivity (GHI) due to the essential role of this system in the regulation of GH action. GHI (OMIM \#262500 and \#245590) was first described in a pediatric setting by Laron et al. ([@B58]), with the description of extreme growth failure in siblings in a consanguineous Jewish family who had the phenotype of hypopituitarism with high serum GH concentrations (Laron, [@B56]). For many years this disorder was referred to as Laron syndrome and was eventually shown to be caused by a defect in the GH receptor (GHR) resulting in deficient binding of ^125^I-GH to GHRs prepared from the patients' liver membranes (Eshet et al., [@B31]). This striking but very rare phenotype, which was also untreatable at that time, became synonymous with the diagnosis of GHI, a perception that remained largely unchallenged for over 20 years. In the late 1980s two pivotal developments brought key changes to the field. The first was the synthesis and availability of recombinant human IGF-I for therapy (Laron et al., [@B57]; Walker et al., [@B95]), and the second was the advent of molecular techniques, which led to the cloning, and characterization of the human *GHR*, thus initiating the understanding of the pathophysiology of GHI (Amselem et al., [@B6]; Godowski et al., [@B36]). The subsequent study of genetic abnormalities in the GH--IGF axis has provided invaluable information on the physiology of human linear growth.

In medicine, scientific advances often move more rapidly than the practices of clinicians, who may remain attached to the recognized, and trusted view of a certain disorder, particularly if it is rare. This has been the case with GHI, which is now known not to be a single entity, but a broad diagnostic category comprising a range of defects affecting the function of the IGF system. These abnormalities may involve genes coding for proteins that regulate GH binding or signal transduction and IGF-I synthesis, transport, or action and are associated with a variety of phenotypes and biochemical abnormalities presenting to the pediatric endocrinologist. This review will describe the individual mutations and discuss the investigation of the child with short stature who has features suggesting the presence of a causative genetic defect.

Previous reviews have often described the characteristics of the extreme phenotype (Rosenfeld et al., [@B81]; Laron, [@B56]; Savage et al., [@B84]), however we concentrate on defects illustrating the range of phenotypes. The article discusses the genetic causes of GHI, also referred to as primary IGF deficiency. We aim also to up-date and orientate clinicians in the appropriate diagnostic approach to children with growth failure.

The GH--IGF Axis in Human Growth
================================

Physiology of GH and the IGF-I system in relation to linear growth
------------------------------------------------------------------

The actions of GH are mediated by a combination of components of the IGF system, including IGF-I, IGF-binding proteins (IGFBPs), the IGF-I receptor (IGFIR), and IGF-independent effects through direct GH action. A diagram of the GH--IGF axis is shown in Figure [1](#F1){ref-type="fig"}. The original "somatomedin hypothesis" proposed that GH binding to its receptor stimulated IGF-I production, which independently affected growth (Salmon and Daughaday, [@B83]). Green et al. ([@B37]) then proposed the "dual effector hypothesis" suggesting that GH regulates the expression of locally produced IGF-I, which then acts in an autocrine/paracrine manner. Expression of the *IGF1* gene was found in multiple tissues throughout embryonic and post-natal development (Roberts et al., [@B77]; Han et al., [@B39]) and injection of GH into hypophysectomized rats increased *IGF1* mRNA in numerous non-hepatic tissues (Lowe et al., [@B62], [@B61]). Direct injection of GH into the cartilage growth plate of hypophysectomized rats also resulted in significantly increased longitudinal bone growth (Isaksson et al., [@B46]). These and other studies suggested that GH has local effects, independent of those mediated by circulating "endocrine" IGF-I. This hypothesis was extended by Isaksson and others (Nilsson et al., [@B70]; Isaksson et al., [@B47]) who demonstrated that GH stimulated differentiation of preadipocytes and chondrocytes in the growth plate, while IGF-I stimulated their clonal expansion.

![**The GH--IGF-I axis in human growth**. Solid arrows, activation processes; dashed arrows, translocation processes. P, phosphorylated residue; Y, tyrosine; AKT, v-akt murine thymoma viral oncogene homolog, also known as PKB, protein kinase B; ALS, acid-labile subunit; IGFBP-3, IGF-binding protein-3; IGFIR, IGF-I receptor; JAK2, Janus kinase 2; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; STAT, signal transducer and activator of transcription.](fendo-02-00095-g001){#F1}

In a comprehensive review of the roles of GH and IGF-I, Le Roith et al. ([@B59]) presented a revised somatomedin hypothesis, taking account of gene deletion experiments in mice that questioned the role of liver IGF-I and its circulating endocrine form in controlling post-natal growth and development (Sjögren et al., [@B87]; Yakar et al., [@B102]). Liver-specific *Igf1* knock-out mice continued to grow normally despite reduction in circulating IGF-I, indicating that locally produced IGF-I was an important growth mediator (Yakar et al., [@B102]). Le Roith has recently modified his conclusions following data showing that when the hepatic *Igf1* transgene was able to elevate serum IGF-I levels growth was largely restored (Wu et al., [@B101]). Kaplan and Cohen ([@B52]) further proposed the apparent paradox that GH exerts its effects through IGFs, some of which oppose the known actions of GH.

Studies using *Igf1* knock-out mouse models have shown that GH stimulates bone growth by IGF-I-independent and IGF-I-dependent mechanisms. Some 75% of serum IGF-I is liver-derived, while the remainder originates from non-hepatic tissues (Sjögren et al., [@B87]; Yakar et al., [@B102]). In addition, serum levels of the acid-labile subunit (ALS) and IGFBP-3 are important in maintaining circulating IGF-I (Ohlsson et al., [@B71]). The importance of ALS was shown in the *Igfals* knock-out mouse model (Ueki et al., [@B90]) and by Domené et al. ([@B28]) who reported the first homozygous mutation in human *IGFALS* causing severe IGF-I deficiency.

Effects of human GH--IGF axis mutations on linear growth
--------------------------------------------------------

Normal GH secretion and the functional integrity of the IGF system are essential for normal linear growth. Defects that have been identified to cause impaired growth are shown in Table [1](#T1){ref-type="table"}. A summary of phenotypic and biochemical features in the range of GH--IGF-I axis defects is given in Table [2](#T2){ref-type="table"}. Human pre-natal growth is regulated principally by nutritional supplies, which influence fetal IGF-I and, perhaps, IGF-II (Derr et al., [@B27]). Targeted disruption of either *Igf1* or *Igf2* in mice led to 40% reduction in fetal growth (Milward et al., [@B67]). The importance of normal IGF-I production in humans was confirmed by the pre-natal growth failure reported in patients with *IGF1* mutations (Jin et al., [@B48]; Rowlinson et al., [@B82]). IGF-I action is also essential as demonstrated by IGFIR rodent knock-out studies (*Igf1r^−/−^*) resulting in 55% reduction in fetal size (Milward et al., [@B67]), an effect also present in humans with mutations of *IGF1R* (Barclay et al., [@B8]). Post-natal growth may be disrupted by mutations that disturb the functional integrity of the cascade of GH--GHR interaction, GH signal transduction, and IGF-I production, transport, and action (Rosenfeld et al., [@B81]; Savage et al., [@B84]). In states of GHI resulting from impaired GH--GHR function, IGF-I deficiency is the cardinal biochemical feature. In mutations specifically involving the *IGF1* or *IGF1R*, GHR function remains intact resulting in possible accentuation of IGF-I-independent GH effects and causing insulin resistance (Rowlinson et al., [@B82]).

###### 

**Genetic defects involving the IGF system and disrupting linear growth**.

  Defects of the GH--IGF-I axis
  ----------------------------------------------------------------
  GH receptor defects
     Extracellular mutations
     Transmembrane mutations
     Intracellular mutations
  GH signal transduction defects (STAT5b)
  Mutations of SHP-2 (encoded by *PTPN11*)
  *IGF1* mutations or deletions
     Defects causing IGF-I deficiency
     Bio-inactive IGF-I
  Acid-labile subunit gene defects
  IGF-I receptor (*IGFIR*) gene mutations
  GH neutralizing antibodies in patients with *GH* gene deletion

*PTPN11, protein tyrosine phosphatase, non-receptor type 11; SHP-2, Src-homology region 2-domain phosphatase-2; STAT, signal transducer and activator of transcription*.

###### 

**Summary of phenotypic and biochemical features in the range of GH--IGF-I axis defects**.

  Gene defect phenotype                           *GHR*   *STAT5b*   *PTPN11*   *IGF-I*   *IGFALS*   *IGFIR*   Bio-inactive GH   *GH1* with anti-GH antibodies
  ----------------------------------------------- ------- ---------- ---------- --------- ---------- --------- ----------------- -------------------------------
  Severe growth failure                           +/−     \+         −          \+        −          −         −                 \+
  Mild growth failure                             −/+     −          \+         −         \+         \+        \+                −
  Mid-face hypoplasia                             +/−     +/−        −          −         −          −         −                 \+
  Other facial dysmorphism                        −       −          \+         \+        −          \+        −                 −
  Deafness                                        −       −          −          \+        −          −         −                 −
  Microcephaly                                    −       −          −          \+        −          \+        −                 −
  Intellectual delay                              −       −          −/+        \+        −          +/−       −                 −
  Puberty delay                                   +/−     +/−        +/−        −         \+         −         −                 −
  Immune deficiency                               −       \+         −          −         −          −         −                 −
  Hypoglycemia                                    \+      −/+        −          −         −          −         −                 −
  Hyperinsulinemia                                −       −          −          \+        \+         −         −                 −
  IGF-I deficiency                                \+      \+         −/+        +/−       \+         −         \+                \+
  IGFBP-3 deficiency                              \+      \+         −/+        −         \+         −         \+                \+
  ALS deficiency                                  \+      \+         −/+        −         \+         −         \+                \+
  GH excess                                       \+      \+         −          +/−       \+         −         −                 −
  GHBP deficiency                                 +/−     −          −          −         −          −         −                 −
  Homozygous or compound heterozygous mutations   \+      \+         −          \+        \+         −         −/+               \+
  Heterozygous mutations                          −       −          \+         −         −          \+        +/−               \_

*+, positive; −, negative; +/−, predominantly positive; −/+, predominantly negative; ALS, acid-labile subunit; IGFBP-3, IGF-binding protein-3; GHBP, growth hormone binding protein*.

Molecular Defects Disrupting the IGF System and Causing Growth Failure
======================================================================

The GH receptor
---------------

The GHR protein mediates the effects of GH on linear growth and metabolism. It is present ubiquitously, being most abundantly expressed in the liver (Chia et al., [@B20]) and is composed of a large extracellular domain involved in GH binding and GHR dimerization, a single transmembrane domain that anchors the receptor to the cell surface and an intracellular domain involved in GH signaling. GH binding activates its receptor by inducing a conformational change in a pre-existing GHR dimer (Adams et al., [@B3]; Wang and Jiang, [@B96]), which promotes the binding of Janus tyrosine kinase 2 (JAK2) to a proline-rich Box 1 region located in the proximal intracellular portion of the GHR (Fowden, [@B35]) and initiates intracellular signaling.

Since 1966, more than 250 patients with genetic GHI have been identified worldwide (Lupu et al., [@B63]; Savage et al., [@B84]). The most severe phenotype was described by Laron et al., [@B58]; *OMIM \#262500*; Laron, [@B56]). Most GHI cases have autosomal recessive inheritance and in the vast majority a molecular defect has been identified involving homozygous or compound heterozygous mutations (Lupu et al., [@B63]). Over 70 mutations of *GHR* have been identified to date ranging from deletions to point mutations including missense, nonsense, and splice mutations (Woods et al., [@B99]; Lupu et al., [@B63]; Savage et al., [@B84]). Among the defects causing aberrant *GHR* splicing, an intronic base change leading to the activation of a pseudoexon sequence and insertion of 36 new amino acids within the receptor extracellular domain was first reported in a consanguineous Pakistani family with mild GHI (Metherell et al., [@B65]). This mutation leads to recognition of the pseudoexon and inclusion of an additional 108 bases between exons 6 and 7 leading to impaired function of the mutant protein (Maamra et al., [@B64]). Intronic mutations resulting in pseudoexon activation are rare in genetic diseases (Akker et al., [@B4]). The phenotypes occurring with this mutation range from severe to mild growth failure (David et al., [@B25]). A mild phenotype of GHI is also associated with heterozygous *GHR* mutations causing a dominant-negative effect (Ayling et al., [@B7]; Iida et al., [@B44]). These splice site mutations (c.876 − 1G \> C) and (c.945 + 1G \> A) form heterodimers with the wild-type GHR and exert a dominant-negative effect on the normal protein.

Differing phenotypes within the same family may also occur, as reported with one sibling having extreme growth failure (adult height --8.7 SDS) and a second a milder phenotype (adult height --6.0 SDS; Milward et al., [@B67]). Both siblings had the same homozygous 22-bp deletion in the cytoplasmic domain of the GHR, resulting in a frameshift and premature stop codon The resultant GHR was truncated at amino acid 449 (GHR1-449) after Box 1, the JAK2 binding domain of the receptor, and functional studies in HEK293 and Chinese hamster ovary cells showed a selective loss of STAT5 signaling in cells expressing GHR1-449 (Milward et al., [@B67]).

A mild phenotype was also reported in two patients with compound heterozygous mutations (Fang et al., [@B32]). Both had undisputed GHI but functional studies suggested incomplete GHR defects that determined the phenotype by an additive effect of each heterozygous mutation. A recent report described a child and his mother with short stature and elevated GH binding protein (GHBP) levels associated with a novel heterozygous C → A transversion at position c.785-3 at the acceptor site of intron 7 (Aalbers et al., [@B1]).

STAT5B mutations
----------------

STAT5B mutations present a characteristic phenotype combining GHI and immunodeficiency *(OMIM \#245590)*. The binding of GH to the GHR activates signaling cascades that include a number of STAT pathways (STAT1, STAT3, STAT5a, and STAT5b). Molecular defects in GH signal transduction pathways appear to be very rare but recent identification of human *STAT5B* mutations causing severe growth failure, IGF-I deficiency, and GHI, demonstrated that STAT5b signaling is critical for GH-induced IGF-I production and normal linear growth (Rosenfeld et al., [@B79]).

In 2003, the first *STAT5B* mutation was identified in a 16-year-old female from a consanguineous Argentine family (Kofoed et al., [@B54]). Subsequent reports confirmed that birth weight in affected patients is generally normal, but is followed by severe post-natal growth failure, with resistance to GH therapy (Hwa et al., [@B42], [@B41]; Bernasconi et al., [@B11]; Vidarsdottir et al., [@B92]). The biochemical profile shows normal or elevated GH secretion, normal GHBP values, and severe deficiencies of IGF-I, IGFBP-3, and ALS which fail to increase on GH stimulation (Hwa et al., [@B42], [@B41]; Bernasconi et al., [@B11]; Vidarsdottir et al., [@B92]). A key feature in all but one reported case (Vidarsdottir et al., [@B92]) was immune dysfunction. In several patients, repeated pulmonary infections occurred from infancy, including episodes of lymphoid interstitial pneumonia (Kofoed et al., [@B54]; Hwa et al., [@B41]), a condition associated with autoimmune disease. Interestingly, interferon-gamma (IFNγ), a cytokine that signals predominantly through the STAT1 pathway, could also up-regulate IGF-I expression but only when STAT5b was present and fully functional (Hwa et al., [@B43]).

The unusual combination of GHI and immune dysfunction in the patient from Argentina led to the identification of a homozygous, missense, mutation in Exon 15 of the *STAT5B* gene (Kofoed et al., [@B54]). The single *G* to *C* transversion at nucleotide 1888 of the *STAT5B* mRNA resulted in an Ala630 (GCT) to Pro (CCT) substitution. Homology modeling with the solved structure of STAT1 (Chen et al., [@B18]) showed that this mutation was within the critical SH2 domain, a well-characterized, conserved, regulatory module that functions by interacting with high affinity to phosphotyrosine-containing target peptides. The Ala630Pro (A630P) substitution was predicted to cause loss of thermodynamic stability as well as aberrant folding and aggregation of the mutant STAT5b protein (Chia et al., [@B19]). It is of note that pathogenic mutations in the SH2 domain of a number of cytoplasmic signaling peptides, including STAT1, have been associated with immuno-deficiencies, but none, except STAT5b, has been associated with severe growth retardation and IGF-I deficiency. Details of the human *STAT5B* mutations reported to date are shown in Figure [2](#F2){ref-type="fig"}.

![**Homozygous *STAT5B* mutations identified in patients with GH insensitivity, IGF-I deficient, severely growth retarded, and immune compromised**. Schematic of the STAT5b protein modular structure encoded by corresponding exons is as indicated. CCD, coiled-coiled domain; DBD, DNA binding domain; L, linker; ND, N-terminal domain; SH2, Src-homology 2-domain; STAT, signal transducer and activator of transcription; TAD, transactivation domain.](fendo-02-00095-g002){#F2}

Since the first report, six other human *STAT5B* mutations have been documented, with several found in siblings (Pugliese-Pires et al., [@B75]). In contrast to mutations in *IGF1* (see below), brain development, and cognitive functions appeared to be normal. The seven *STAT5B* mutations, located in different domains of the STAT5b protein, comprise two missense mutations, p.A630P and p.F646S, a nonsense mutation, p.R152X, single nucleotide insertions, c.*1191insG* and c.*1103insC*, nucleotide deletions c.*1680delG* and c.*424_427del*. The insertion/deletion mutations result in frameshifts and truncation of the STAT5b protein. All reported mutations were homozygous and autosomal recessive. The phenotype of STAT5b-deficient patients includes profound short stature and delayed puberty in the older subjects. The only patient without obvious immune deficiency, the first reported male proband, contracted hemorrhagic varicella at 16 years of age and had congenital ichthyosis, but, otherwise, appeared healthy (Vidarsdottir et al., [@B92]) One other patient was diagnosed with juvenile idiopathic arthritis at the young age of 2 years. Immunological evaluations reported for one of the patients carrying p.R152X, indicated lymphopenia and abnormally low regulatory T cells, similar to the proband carrying the p.A630P mutation (Cohen et al., [@B23]). It is also of note that STAT5b deficiency was associated with abnormally high levels of circulating prolactin in six of the cases. It remains unclear whether the hyperprolactinemia is a direct or indirect consequence of *STAT5B* mutations.

IGF1 mutations
--------------

The first human *IGF1* defect was described by Woods et al., [@B100]; *OMIM \#608747*). Features of patients with *IGF-I* defects are shown in Table [3](#T3){ref-type="table"}. The first patient, a male, was born by Caesarian section because of poor fetal growth. Placental weight was diminished (350 g) and he had severe intrauterine growth retardation (IUGR) with a birth weight of 1.4 kg (--3.9 SDS), birth length of 37.8 cm (--5.4 SDS), and microcephaly (head circumference 27 cm, --4.9 SDS). His growth failure worsened post-natally and at 15.8 years, his height was 119.1 cm (--6.9 SDS), and his weight was 23.0 kg (--6.5 SDS). He had delayed psychomotor development and sensorineural deafness. During adolescence he became insulin resistant. No IGF-I was detected in the serum even after 4 days of stimulation with GH in an IGF-I generation test (IGFGT). Spontaneous 12-h GH secretion showed abnormally elevated baseline and peaks. ALS and IGFBP-3 values were normal. Molecular analysis revealed a homozygous deletion of exons 4 and 5 of the *IGF1* gene. If translated, the resulting protein would be severely truncated, lacking 45 of the 70 IGF-I amino acids (Woods et al., [@B100]). At 16.1 years (bone age, 14.2 years), recombinant IGF-I therapy was initiated and resulted in beneficial effects on insulin sensitivity, body composition, bone size, and linear growth (Camacho-Hübner et al., [@B17]; Woods et al., [@B97]).

###### 

**Characteristics of six cases with *IGF1* defects**.

                                   Woods et al. ([@B100])   Bonapace et al. ([@B14])   Walenkamp et al. ([@B94])   Netchine et al. ([@B68])   van Duyvenvoorde et al. ([@B91])   van Duyvenvoorde et al. ([@B91])
  -------------------------------- ------------------------ -------------------------- --------------------------- -------------------------- ---------------------------------- ----------------------------------
  **OBSERVATION**                                                                                                                                                                
  Sex                              Male                     Male                       Male                        Male                       Female                             Male
  Consanguinity                    Yes                      Yes                        Yes                         Yes                        No                                 No
  Birth weight (SDS/g)             −3.9/1400                −4.0/1480                  −2.5/1420                   −2.5/2350                  −2.9/2300                          −1.2/3300
  Birth length (SDS/cm)            −5.4/37.8                −6.5/41                    −3/39                       −3.7/44                    −3.8/44.0                          −1.0/50.0
  Cranial circumference (SDS/cm)   −4.9/27                  −7.5/26.5                  −8.0/44.2                   −2.5/32                    −2.4/47.8                          −1.6/49.0
  Growth (SDS)                     −6.9 at 16 years         −6.2 at 1.6 years          −9 at 55 years              −4.5 at 3 years            −4.1 at 8.2 years                  −4.6 at 6.2 years
  Microcephaly                     Yes                      Yes                        Yes                         Yes                        Yes                                Mild
  Development delay                Yes                      Yes                        Yes                         Mild                       Yes                                No
  Deafness                         Yes                      Yes                        Yes                         No                         No                                 No
  Adiposity                        Yes                      No                         Yes                         No                         No                                 No
  **HORMONAL EVALUATION**                                                                                                                                                        
  IGF-I levels                     Undetectable             1.0 ng/mL                  +7.3 SDS                    Variable                   −2.3 SDS                           −2.6 SDS
  IGFBP-3 levels                   3.3 mg/L                 3.6 mg/L                   1.98 mg/L (+0.1 SDS)        4.3 mg/L                   +1.2 SDS                           +0.1 SDS
  Molecular defect                 Hom p.? (Del ex 4--5)    Hom p.? \*\*               Hom p.V44M                  Hom p.R36Q                 Het *c.243*−*246dupCAGC*           Het *c.243*−*246dupCAGC*
  IGF1R affinity                   Zero                     Not studied                Extremely low               Partially reduced          Not studied                        Not studied

*IGFBP-3, IGF-binding protein-3; SDS, standard deviation score; Hom, homozygous defect; Het, single heterozygous defect*.

*^\*\*^This mutation is localized within the polyadenylation site and alters mRNA splicing. The 3′ end of the resulting aberrant IGF-I transcript contains a partial sequence from the downstream gene KIAA0537*.

Features of IUGR, microcephaly, retarded intellectual development and severe post-natal growth failure were present in the other cases with homozygous *IGF1* mutations (Bonapace et al., [@B14]; Walenkamp et al., [@B94]; Netchine et al., [@B68]). Deafness was present in all the cases except the child with the mildest phenotype (Netchine et al., [@B68]). The microcephaly shown by these patients, is a cardinal feature of the phenotype and allows a distinction with Russell--Silver syndrome patients, who have a relative macrocephaly (Netchine et al., [@B69]). There has been some variation of serum IGF-I levels in the reported *IGF1* mutation cases. The third case to be described (Walenkamp et al., [@B94]) shared an identical clinical phenotype with the index case (Woods et al., [@B100]), and had a younger brother with similar features who died in childhood. This patient had a serum IGF-I level that was significantly increased (+7.3 SDS), explained by the fact that the patient's homozygous missense mutation of *IGF1*, a G → A nucleotide substitution at position 274, changing valine at position 44 in the A domain of the mature IGF-I protein to methionine (p.V44M), resulted in a recombinant protein (IGF1 V44M) which allowed normal binding to IGFBP-3 but decreased affinity (90-fold) for its receptor, IGF1R. This patient therefore had bio-inactive IGF-I caused by an *IGF1* mutation. Serum IGF-I levels in the fourth patient who had a relatively mild phenotype were also variable and not severely decreased (Netchine et al., [@B68]). In all reported subjects serum IGFBP-3 and ALS levels have been normal or elevated.

Genetic analysis of *IGF1* in the second case (Bonapace et al., [@B14]) showed a homozygous T → A transversion in exon 6, that would result if translated into an altered E domain of the IGF-I precursor. It has been argued that this variant may be a polymorphism and thus not causative of the patient's phenotype, which was nevertheless strikingly similar to the other cases. In the patient with the mild phenotype, sequencing of *IGF1* revealed a homozygous missense mutation resulting in the change of a highly conserved arginine located in the C domain of the protein into a glutamine (p.R36Q). Affinity for the IGF1R decreased two to threefold, resulting in decreased IGF1R autophosphorylation. This partially diminished IGF-I activity had marked consequences for fetal growth and development (Netchine et al., [@B68]).

IGFALS mutations
----------------

*IGFALS* mutations are associated with GHI and severe ALS and IGF-I deficiencies (*OMIM \#601489)*. The ALS is a soluble protein and member of the leucine-rich repeat family, and is expressed by hepatocytes and secreted into the blood stream (Leong et al., [@B60]). GH is the main inducer of ALS synthesis (Ooi et al., [@B72]) and in the circulation ALS can be found free or bound to IGF-I or -2 and IGFBP-3 or -5, to form a ternary complex (Baxter, [@B10]), which prevents IGFs, free or bound to IGFBPs, from leaving the circulation, thus prolonging their half-lives and decreasing their availability at a tissue level. ALS is encoded by the *IGFALS*, located on chromosome 16p13.3 and spanning 3.3 Kb. Inactivation of the *IGFALS* in mice results in absence of circulating ALS but only modest growth failure despite marked reduction of serum IGF-I and IGFBP-3 levels (Ueki et al., [@B90]).

The first patient with a homozygous mutation of *IGFALS* was reported by Domené et al. ([@B28]) and presented a new combination of genetic, biochemical, and phenotypic data. The most striking feature of this genetic defect causing GHI was a mis-match between extreme deficiencies of circulating IGF-I, IGFBP-3, and ALS and relatively mild growth failure, even leading to a normal adult height in some patients (Domené et al., [@B30]). A recent review of published cases confirms these features (Domené et al., [@B29]). Sixteen different mutations of the human *IGFALS* gene (Figure [3](#F3){ref-type="fig"}) have been identified in 21 cases (Domené et al., [@B29]). Eleven were homozygous and six were compound heterozygous with autosomal recessive inheritance. *IGFALS* mutations have included missense and nonsense mutations, deletions, duplications, and insertions resulting in frameshift and premature stop codons and in-frame duplication mutations leading to insertion of extra amino acid residues (Domené et al., [@B29]). In all cases, there was extreme deficiency of circulating ALS, with inability to form the ternary complex (Domené et al., [@B29]; David et al., [@B26]). Whereas circulating levels of IGF-I and IGFBP-3 are severely reduced, due to their rapid clearance, local production of IGF-I in peripheral tissues, notably the growth plate, appears to be preserved or even increased due to up-regulation of GH secretion (Domené et al., [@B28]). Insulin resistance, with hyperinsulinemia and low IGFBP-1, has also been described in these patients (Heath et al., [@B40]; Domené et al., [@B29]).

![**Schematic representation of the ALS protein indicating the location of identified human *IGFALS* mutations**. The *IGFALS* is composed of two exons, with five amino residues of the ALS signal peptide encoded by exon 1 and the first five amino residues of exon 2 and the remainder of the ALS protein encoded by exon 2. ALS, acid-labile subunit; NH~2~, N-terminal region.](fendo-02-00095-g003){#F3}

Recently attention has focused on the possible effect of heterozygous *IGFALS* mutations on growth. An analysis of 21 patients with homozygous or compound heterozygous *IGFALS* mutations and their family members who were either heterozygous carriers or homozygous wild-type normal has recently been published (Fofanova-Gambetti et al., [@B34]). Mean height SDS was --2.31 ± 0.87 in the homozygous *IGFALS* mutation patients. Analyses within individual families showed that heterozygosity for *IGFALS* mutations resulted in approximately 1.0 SD height loss in comparison with wild-type, whereas homozygosity or compound heterozygosity resulted in a further loss of 1.0--1.5 SD, suggestive of a gene-dosage effect.

IGFIR mutations
---------------

*IGFIR* mutations are characterized by IGF-I resistance causing impaired fetal and post-natal growth (*OMIM \#270450)*. The IGF1R is a transmembrane receptor and belongs to the insulin receptor family, which includes the IGF2R and insulin receptor. The IGFIR is expressed widely and binds IGF-I and -2 with high affinity, mediating their biological actions by activating a complex intracellular signaling cascade leading to the transcription of IGF target genes. The *IGF1R* gene is located on chromosome 15q26.3 and spans 315 kb.

Mutations in *IGF1R* were first reported by Abuzzahab et al. ([@B2]) following analysis of DNA from cohorts of children with short stature and unexplained IUGR. The first child was a compound heterozygote for point mutations in exon 2 of the *IGFIR* gene that altered the amino acid sequence to p.R108Q in one allele and p.K115N in the other. She had a birth weight of --3.5 SD with childhood short stature and an adult height of --4.8 SD. The second patient, a boy, had a heterozygous nonsense mutation (p.R59X) that reduced the number of IGF1Rs on fibroblasts. He also had low birth weight (--3.5 SD) and birth length (--5.8 SD) with microcephaly and post-natal growth failure (height --3.8 SD) at age 14 months and some additional dysmorphic features. Serum IGF-I levels were normal or elevated in both patients and GH secretion was within normal limits.

There have been several reports of familial short stature due to *IGF1R* mutations. A heterozygous mutation in the cleavage site of the proreceptor of *IGF1R* was reported in a 6-year-old Japanese girl and her mother (Kawashima et al., [@B53]) and the group of Wit in Leiden described a mother and daughter with a heterozygous missense mutation in the intracellular part of the *IGF1R* (Walenkamp et al., [@B93]). A 9-year-old male patient (height --3.6 SD), his sister (height --1.94 SD and IUGR), and his mother (height --4.6 SDS) carried the same *IGF1R* mutation which was a novel heterozygous 19-nucleotide duplication in exon 18 (Fang et al., [@B33]). Functional studies in primary dermal fibroblasts derived from the patient and family members indicated that *IGF1R* mRNA expressed from the mutant allele was degraded through the nonsense-mediated mRNA decay pathway resulting in reduced amount of wild-type IGF1R protein and, subsequently, diminished activation of the IGF1R pathway. A further female child was reported with a heterozygous missense mutation in the highly conserved N-terminal fibronectin type III domain of *IGF1R* with functional studies demonstrating impaired post-receptor IGF-I signaling (Inagaki et al., [@B45]).

GH1 mutations causing biologically inactive GH
----------------------------------------------

Certain *GH1* mutations cause biologically inactive GH resulting in a form of GHI (*OMIM \#262650*). A syndrome of biologically inactive GH causing GHI and short stature was first described by Kowarski et al. ([@B55]). The molecular basis of this apparently rare cause of GHI was clarified by Takahashi et al. ([@B88], [@B89]) who reported two cases with heterozygous mutations in the *GH1* gene. The first case was a boy with severe short stature (height −6.1 SD) who had increased immunoassayable GH and IGF-I deficiency, which responded, as did his growth, to exogenous hGH therapy. The mutation was a single-base missense substitution (p.R77G) in exon 4 of the *GH1*. However his normal stature father also had the same mutation. Functional studies demonstrated that the mutant GH molecule had higher binding affinity for the GHR and inhibited its activation by wild-type GH in a dominant-negative fashion, thus impairing GH bioactivity. The second case was a girl with similar endocrine features and short stature associated with a heterozygous single-base change (A → G) causing a p.D112G substitution in *GH1*. More recently, a child with short stature (height −3.6 SD at age 9 years) from a consanguineous Serbian family was reported to have a homozygous missense mutation, C53S, of *GH1* leading to the absence of the disulfide bridge Cys-53 to Cys-165 in the GH molecule (Besson et al., [@B12]).

GH1 gene deletions (type IA GH deficiency) with anti-GH antibodies
------------------------------------------------------------------

A rare form of GHI occurs due to acquired GH-inhibiting antibodies in a category of children with familial isolated GH deficiency (IGHD; *OMIM \#262400*; Cogan and Phillips, [@B22]). Autosomal recessive IGHD, caused by gross deletions of the *GH1*, result in severe IGHD (Type IA) with undetectable GH secretion (Phillips et al., [@B73]). Such patients have severe post-natal growth failure with height usually \<−4.5 SD. Most of the *GH1* deletions are 6.7, 7.0, or 7.6 kb in length, although several of 45 kb have been reported (Proctor et al., [@B74]). Microdeletions and frameshift mutations have also been reported (Baumann, [@B9]; Cogan and Phillips, [@B22]; Alatzoglou and Dattani, [@B5]). IGHD patients with homozygous deletions of the *GH1* gene frequently develop anti-GH antibodies during treatment with GH due to immunological intolerance. However, variability of both antibody formation and response to GH therapy may occur, even within families (Proctor et al., [@B74]). Rare homozygous microdeletions and single base-pair substitutions in the *GH1* coding region have also resulted in anti-GH antibody formation during GH therapy. The formation of anti-GH antibodies neutralizes the growth response to GH therapy, resulting in a state of GHI associated with severe short stature. Such patients may respond to therapy with recombinant human IGF-I, which becomes the only effective management for their growth failure (Riedl and Frisch, [@B76]).

The Investigation of GH--IGF-I Axis Mutations
=============================================

The evaluation of a child with short stature and a possible GH--IGF-I axis mutation should comply with the classical paradigm of clinical assessment followed by general (i.e., non-endocrine) investigations, hormonal assessment, and appropriate genetic analyses. An algorithm showing key steps in the investigation of genetic GH--IGF-I axis defects is shown in Figure [4](#F4){ref-type="fig"}. As advances in molecular endocrinology related to growth disorders progress, the crucial importance of detailed phenotypic evaluation and documentation becomes increasingly important. The urge to obtain a possible molecular diagnosis at the onset of the investigations should be resisted until detailed clinical and endocrine evaluation has been performed. Clinical assessment should include enquiries about family history of growth disturbance, consanguinity, birth weight and length, and recurrent infections (Savage et al., [@B85]). Examination should specifically assess the presence of possible facial dysmorphic features and microcephaly in addition to anthropometric evaluation (Cohen et al., [@B24]).

![**Algorithm showing key steps in the investigation of genetic GH--IGF-I axis defects**. SD, standard deviation; IGHD, isolated growth hormone deficiency; ALS, acid-labile subunit; IGFBP-3, IGF-binding protein-3.](fendo-02-00095-g004){#F4}

Investigations of the GH--IGF-I axis
------------------------------------

Investigations of the GH--IGF-I axis consist of determination of GH secretion and exploration of the IGF system. A GH provocation test is recommended unless the child has normal auxology or a basal IGF-I level above the mean for age (Cohen et al., [@B24]). In a child with clinical criteria of GHD, a peak GH level of \<10 ng/mL has traditionally been used to support this diagnosis (Growth Hormone Research Society, [@B38]). Basal IGF-I levels should also be determined, although these may be influenced by factors such as age, nutrition, chronic illness, and puberty. In the initial assessment, IGFBP-3 adds little, except in children under 3 years of age, where low IGFBP-3 is helpful in the diagnosis of GHD (Cianfarani et al., [@B21]). Reliable assay performance and appropriate normative data (Juul et al., [@B50], [@B51]) are essential for the use of IGF-I and IGFBP-3 in clinical practice, and adjustment for sex, age, puberty, and nutritional status is recommended.

A diagnosis of GHI follows from the demonstration of abnormal auxology, normal GH secretion, and IGF-I deficiency. However, the pathogenesis will not have been elucidated from these investigations. The nature of the defect can often be defined by additional measurement of IGFBP-3, ALS, and GHBP (Savage et al., [@B85]). In *GHR* defects IGF-I, IGFBP-3, and ALS are decreased (Burren et al., [@B16]), although the degree of abnormality can vary with the type of mutation, which also influences GHBP levels. GH secretion is elevated in most patients with severe IGF-I deficiency.

The IGF-I generation test
-------------------------

The principle behind the design of the IGFGT was that repeated injections of GH induce measurable increases of IGF-I, IGFBP-3, and ALS secretion. However, in GH deficiency patients, the degree of IGF-I response did not convincingly predict the growth response to GH therapy (Rosenfeld et al., [@B80]). Normative data were not established and the test is not used for this purpose. Interest in the IGFGT was renewed when molecular evidence of GHI was demonstrated and subjects were selected for rhIGF-I therapy. Criteria for diagnosis of GHI were defined as: failure to increase IGF-I and IGFBP-3 by \>15 and 400 ng/mL, respectively (Blum et al., [@B13]; Woods et al., [@B98]). However, as the spectrum of GHI disorders expanded, these criteria are now too strict for mildly affected subjects and even in severe GHI patients, post-GH increases of IGF-I ranged from \<20 to 58 ng/mL and of IGFBP-3 from 95 to 1762 ng/mL (Rosenfeld, [@B78]). Attempts to refine the IGFGT for the diagnosis of milder GHI have demonstrated that patients with idiopathic short stature produced a subnormal response (Selva et al., [@B86]) and subjects with IGF-I deficiency and normal GH secretion also had subnormal ability to generate IGF-I (Midyett et al., [@B66]). However, additional sensitivity for the diagnosis of GH resistance was not seen with a low-dose GH protocol (Buckway et al., [@B15]). A lack of reproducibility of IGF-I and IGFBP-3 responses in the IGFGT has also been reported (Jorge et al., [@B49]). For this reason genetic analysis and assessment of the growth response to GH therapy, especially in patients without the classical GHI phenotype, should be performed to confirm GH resistance. The principal value of the IGFGT is the confirmation of extreme or severe GHI (Rosenfeld et al., [@B81]; Woods et al., [@B98]).

Genetic investigations
----------------------

The discussions above have indicated that genetic mutations in the GH--IGF-I axis make a major contribution to the pathogenesis of GHI. Following clinical and biochemical assessment and where a genetic cause of short stature is expected from the family history, DNA analysis for key candidate genes can confirm a genetic diagnosis. A hierarchy and priority of molecular tests can be defined following careful clinical and biochemical assessment. Testing for molecular defects in the GH--IGF-I axis is not commercially available at the present time. However, there are a number of academic laboratories that perform DNA sequencing studies of the relevant candidate genes. *In vitro* functional studies may also be necessary to quantitate the degree of protein dysfunction, particularly in cases with a milder phenotype. There are many components of the GH and IGF signaling cascades that remain poorly understood and are legitimate candidates for harboring significant mutations and/or deletions. Thus the absence of identifiable mutations in the candidate genes described above cannot rule out the possibility of a molecular abnormality of the GH--IGF axis.

Ideally family members should also be tested. It is now clear that members of the same family with the same mutations may have differing phenotypes Milward et al., [@B67]). Additionally, for many of the autosomal recessive disorders described above, the issue of heterozygous expression remains of great interest and is worthy of further study (Fofanova-Gambetti et al., [@B34]; van Duyvenvoorde et al., [@B91]).

Conclusion
==========

From the fundamental importance of the GH--IGF axis in human linear growth, it follows that defects at many points in this axis will result in growth impairment leading to short stature. The key defects leading to GHI have been described and the range of genetic, clinical, and biochemical abnormalities, both within each genetic disorder and within the spectrum of GHI disorders as a whole has been emphasized. GHI can no longer be considered to be a single clinical entity, as it was envisaged nearly 50 years ago. As new genetic defects leading to an expansion of the field of GHI are described, each new mutation will itself contribute to the genetic and phenotypic continuum. Although the precise etiology in many children with short stature remains uncertain, the investigation of patients with abnormal growth should be encouraged in order to improve diagnosis and contribute to science.
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